Penelope Pauley
Pediatric Endocrinology · Orlando, FLNPI 1538489299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $943, 2.6 times the $366 reported in 2019.
Across 95 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$372
- Insulet Corporation$339
- Ascendis Pharma Endocrinology Inc$306
- Sanofi-aventis U.S. LLC$192
- Tandem Diabetes Care, Inc.$191
- Endo Pharmaceuticals Inc.$191
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,55697%
- Education$883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $372 |
| Insulet Corporation | 10 | $339 |
| Ascendis Pharma Endocrinology Inc | 13 | $306 |
| Sanofi-aventis U.S. LLC | 4 | $192 |
| Tandem Diabetes Care, Inc. | 8 | $191 |
| Endo Pharmaceuticals Inc. | 5 | $191 |
| AbbVie | 4 | $159 |
| Dexcom, Inc. | 1 | $123 |
| Tolmar, Inc. | 6 | $120 |
| Eton Pharmaceuticals, Inc. | 3 | $96 |
| Pfizer | 4 | $94 |
| Neurocrine Biosciences, Inc. | 2 | $74 |
| Tolmar Pharmaceuticals, Inc. | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 2 | $47 |
| Medtronic | 2 | $41 |
| Lilly USA, LLC | 2 | $31 |
| BETA Bionics, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Sandoz | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $16 |
| Endo USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$229
- SUPPRELIN$126
- DEXCOM G7 GSS (161)$123
- Yorvipath$122
- TZIELD$112
- Lupron Depot$103
How this compares
$2,643 in reported general payments places this provider in the 55th percentile of 102 pediatric endocrinology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $21,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $31 | $21,43521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Orlando
- Joshua YangOrlando$846K
- Matthew BensonOrlando$32K
- Neha VyasOrlando$6K
- Erin GreenupOrlando$6K
- Jennifer VillarOrlando$3K
- Michelle Rivera-VegaOrlando$3K
- Paul DesrosiersOrlando$3K
- Richard BanksOrlando$2K
- Katherine VelezOrlando$2K
- Shadi TabbaOrlando$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.